Background: Elevation of the marker neopterin is associated with the progression and consequences of diabetes. Although the clinical relationship between the high levels and peripheral neuropathies other than diabetic peripheral neuropathy is unknown, it has been linked to them. Objective: To evaluate the difference in serum neopterin levels between diabetic individuals who have peripheral neuropathy and those who do not. Methods: This seven-month cross-sectional study at the Diabetic Center began in December 2022 and included 126 patients with the second type of diabetes mellitus. Following verbal consent, the included patients were subjected to neurological and physical evaluations. Along with the blood pressure, the weight and height were noted. Glucose, TG, CH, HDL-c, fasting insulin, and neopterin were all analyzed using serum. Formulas were used to compute BMI, LDL-c, and VLDC. Results: When diabetic individuals with peripheral neuropathy were compared to those without, the serum levels of neopterin in the former group revealed a marginally higher level than in the latter, but this difference was not statistically significant. Conclusion: Neopterin levels were not altered in diabetic individuals with peripheral neuropathy, indicating that it is not a reliable indicator of the condition.
BACKGROUND : Smoking disrupts the endocrine system, altering levels of key hormones such as estrogen (E2) and prolactin (PRL). This makes the relationship between smoking and sex hormones an important research topic. IL-12 is a crucial cytokine that enhances immune responses, particularly in promoting T-cell differentiation. AIM: This study aims to assess the impact of smoking on immune function by analyzing the reduction of pro-inflammatory cytokines (e.g., IL-12) and determining whether hormonal differences exacerbate this effect in females. MATERIALS AND METHODS : Ninety serum samples were collected from healthy single females, age range (20–29) years old. The samples were divided into three groups: smokers (n=30), secondhand smokers (individuals exposed to tobacco smoke in their environment) (n=30), and non-smokers (control group, n=30). The female smokers were subdivided into 2 sub-groups: the first is based on the rate of smoking per day into heavy and light smokers, and the second group is the duration of smoking years (<4 years) and (≥4 years). RESULTS : The findings revealed notable variations in the levels of IL-12, PRL, and HbA1c across all the studied groups (p-value <0.05). While, for E2, the (Median=92.68) in the smokers is lower than the control and secondhand smokers groups, the difference is non-significant. CONCLUSION : Our findings suggest that heavy smoking adversely affects both metabolic health (increases HbA1c level) and hormonal balance in women. Also, smoking does decrease IL-12 levels, which can impair immune responses and affect overall health. While the durations of smoking (short-term vs. long-term) did not lead to notable changes in the outcomes being measured.
Exposure to ionizing radiation destroys several biological processes by disturbing the membranes of cells and causing damage to DNA, proteins, and mitochondria. Increasing the use of ionizing radiation-based treatment and diagnosis techniques has been associated with the increased chronic diseases among healthcare occupational and patients. However, numerous factors such as duration of exposure, radiation dose, dose rate, the organs of the body exposed, and the person's age impact the ionizing radiation-induced chronic effect. Exposure to ionizing radiation has various harmful effects on healthy tissues; long-term exposure to radiation increases the risk of carcinogenesis and autoimmune diseases such as diabetes. A recent study has also highlighted its potential role in the development of diabetes. This review examines the linkage between radiation-induced DNA damage and diabetes and Explores how radiation can contribute to the emergence and worsening of this chronic metabolic disorder. This review study aims to offer an exhaustive summary of how radiation-induced DNA damage promotes diabetes hazards, highlighting areas for future studies. Also, taking oral antioxidants to protect from radiation-induced DNA damage and mitigate oxidative damage and inflammatory markers after radiation exposure may reduce the incidence of diabetes. Radiation can cause damage to DNA through ionization, which creates free radicals that attack the DNA structure, leading to mutations or breaks in the DNA strands. If this damage occurs in cells involved in glucose regulation or insulin production, it may contribute to the development of diabetes.
Background. Staphylococcus aureus, is a major pathogen causing infections in both hospital and community settings. Multi-drug-resistant strains, particularly Methicillin-resistant Staphylococcus aureus (MRSA), complicate treatment, as these strains can evade antibiotics. Biofilm formation by S. aureus protects bacterial cells from immune responses and antibiotics, making infections difficult to treat. This study evaluates the synergistic effect of silver nanoparticles (AgNPs) and cefotaxime in inhibiting biofilm formation by clinical S. aureus isolates, especially multi-drug-resistant strains. Materials and Methods. Thirty clinical S. aureus isolates were obtained from patients with skin infections. Identification was confirmed using biochemical tests and the VITEK2 system. Antimicrobial susceptibility testing was performed using the disk diffusion method on antibiotics including ciprofloxacin, imipenem, amoxicillin-clavulanic acid, cefotaxime, and chloramphenicol. Minimum inhibitory concentrations (MICs) were also determined. Biofilm formation was quantified using crystal violet staining. Silver nanoparticles (AgNPs) were synthesized using sodium borohydride and characterized by atomic force microscopy (AFM) and field emission scanning electron microscopy (FE-SEM). Results. All isolates were susceptible to ciprofloxacin and imipenem. Ninety percent were susceptible to amoxicillin-clavulanic acid, while 70% were susceptible to cefotaxime. All isolates were resistant to chloramphenicol. Biofilm formation assays showed variability in biofilm production. AgNPs alone demonstrated superior efficacy in inhibiting biofilm formation. The combination of AgNPs and cefotaxime exhibited the strongest inhibition, suggesting a synergistic effect. Conclusion. This study suggests that AgNPs alone are more effective than cefotaxime in inhibiting biofilm formation. The combination of AgNPs and cefotaxime showed the most potent effect, providing a promising strategy for treating multi-drug-resistant S. aureus infections. AgNPs may serve as an adjunct to antibiotics in overcoming biofilm-associated infections.
Introduction Type 2 diabetes mellitus (T2DM) prevalence in Iraq is projected to rise significantly by 2045, creating urgent need for optimized use of latest insulin therapies. An expert panel of eleven diabetes specialists convened to assess the evolving landscape of insulin therapies and explore how each option fits into current strategies to optimize T2DM management in Iraq. Methods The panel reviewed international guidelines and local practice patterns through pre-meeting surveys. Discussions focused on initiation and intensification of insulin-based treatment in Iraq's context, considering accessibility challenges and patient characteristics. Results When hemoglobin A1c (HbA1c) is < 2% above target, basal insulin (BI) is recommended for patients with body mass index (BMI) ≤ 30. For BMI > 30, either GLP-1 receptor agonist (GLP-1 RA) monotherapy or a fixed ratio combination (FRC) of GLP-1 RA and BI is preferred. When HbA1c is ≥ 2% above target, initiation with BI and GLP-1 RA is advised across BMI groups. If glycemic targets are not achieved despite reaching 0.5 U/kg of BI, prandial insulin may be added via premixed regimen or basal–bolus regimens based on individual factors. Premix insulin remains an alternative when other options are unavailable. Key barriers in Iraq include high cost and limited availability of GLP-1 RAs, therapeutic inertia, and gaps in healthcare infrastructure. Final treatment decisions should consider disease severity, cardiovascular and renal comorbidities, and weight goals. Conclusion The panel curated clinical practical recommendations about injectable insulin therapies and proposed a structured treatment algorithm tailored to Iraq’s healthcare setting, prioritizing simplicity, efficacy, tolerability and accessibility. The panel emphasized the critical role of second-generation BIs and FRCs of BI and GLP-1 RA in Iraq’s T2DM treatment algorithm, providing clear guidance on their optimal use and place in therapy, overcoming barriers, alongside enhanced education for healthcare providers and patients.